Refametinib
As of the edition of 20 October 2026, Refametinib is a small molecule: went quiet in 2017; acts on MAP2K1 and MAP2K2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2017
- Kind
- Small molecule
- Registered trials
- 11, 1 stopped early
- Disease areas
- Cancer; Digestive system; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product2 company-target rows are on route A because of Refametinib.
See the 2 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 6 | 5 | 0 | 1 |
| Phase 2 | 5 | 5 | 0 | 0 |
| All trials | 11 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Bayer | Lead sponsor of trials | 2007 to now |